📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. (2024)

First Author: Cavanagh RJ

Attributed to: Radiotherapy activated materials for enhanced cancer treatments funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1039/d3bm01931d

PubMed Identifier: 38407276

Publication URI: http://europepmc.org/abstract/MED/38407276

Type: Journal Article/Review

Volume: 12

Parent Publication: Biomaterials science

Issue: 7

ISSN: 2047-4830